These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

207 related articles for article (PubMed ID: 17009300)

  • 21. Discovery of [3-(4,5,7-trifluoro-benzothiazol-2-ylmethyl)-pyrrolo[2,3-b]pyridin-1-yl]acetic acids as highly potent and selective inhibitors of aldose reductase for treatment of chronic diabetic complications.
    Van Zandt MC; Doan B; Sawicki DR; Sredy J; Podjarny AD
    Bioorg Med Chem Lett; 2009 Apr; 19(7):2006-8. PubMed ID: 19250825
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Novel, highly potent aldose reductase inhibitors: cyano(2-oxo-2,3-dihydroindol-3-yl)acetic acid derivatives.
    Da Settimo F; Primofiore G; Da Settimo A; La Motta C; Simorini F; Novellino E; Greco G; Lavecchia A; Boldrini E
    J Med Chem; 2003 Apr; 46(8):1419-28. PubMed ID: 12672241
    [TBL] [Abstract][Full Text] [Related]  

  • 23. On-bead combinatorial techniques for the identification of selective aldose reductase inhibitors.
    Robins LI; Dixon SM; Wilson DK; Kurth MJ
    Bioorg Med Chem; 2006 Dec; 14(23):7728-35. PubMed ID: 16931029
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Design and synthesis of highly potent and selective (2-arylcarbamoyl-phenoxy)-acetic acid inhibitors of aldose reductase for treatment of chronic diabetic complications.
    Van Zandt MC; Sibley EO; McCann EE; Combs KJ; Flam B; Sawicki DR; Sabetta A; Carrington A; Sredy J; Howard E; Mitschler A; Podjarny AD
    Bioorg Med Chem; 2004 Nov; 12(21):5661-75. PubMed ID: 15465344
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Structure-based optimization of aldose reductase inhibitors originating from virtual screening.
    Eisenmann M; Steuber H; Zentgraf M; Altenkämper M; Ortmann R; Perruchon J; Klebe G; Schlitzer M
    ChemMedChem; 2009 May; 4(5):809-19. PubMed ID: 19301313
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Synthesis and activity of a new series of (Z)-3-phenyl-2-benzoylpropenoic acid derivatives as aldose reductase inhibitors.
    Wang SJ; Yan JF; Hao D; Niu XW; Cheng MS
    Molecules; 2007 Apr; 12(4):885-95. PubMed ID: 17851441
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Phenolic 4-hydroxy and 3,5-dihydroxy derivatives of 3-phenoxyquinoxalin-2(1H)-one as potent aldose reductase inhibitors with antioxidant activity.
    Zou Y; Qin X; Hao X; Zhang W; Yang S; Yang Y; Han Z; Ma B; Zhu C
    Bioorg Med Chem Lett; 2015 Sep; 25(18):3924-7. PubMed ID: 26227780
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Protein structure-based de novo design and synthesis of aldose reductase inhibitors.
    Iwata Y; Naito S; Itai A; Miyamoto S
    Drug Des Discov; 2001; 17(4):349-59. PubMed ID: 11765138
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Discovery of boronic acids as novel and potent inhibitors of fatty acid amide hydrolase.
    Minkkilä A; Saario SM; Käsnänen H; Leppänen J; Poso A; Nevalainen T
    J Med Chem; 2008 Nov; 51(22):7057-60. PubMed ID: 18983140
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Synthesis and aldose reductase inhibitory activities of novel thienocinnolinone derivatives.
    Pau A; Asproni B; Boatto G; Grella GE; De Caprariis P; Costantino L; Pinna GA
    Eur J Pharm Sci; 2004 Mar; 21(4):545-52. PubMed ID: 14998586
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Identification of new non-carboxylic acid containing inhibitors of aldose reductase.
    Maccari R; Ciurleo R; Giglio M; Cappiello M; Moschini R; Corso AD; Mura U; Ottanà R
    Bioorg Med Chem; 2010 Jun; 18(11):4049-55. PubMed ID: 20452228
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Novel 5alpha-reductase inhibitors: synthesis, structure-activity studies, and pharmacokinetic profile of phenoxybenzoylphenyl acetic acids.
    Salem OI; Frotscher M; Scherer C; Neugebauer A; Biemel K; Streiber M; Maas R; Hartmann RW
    J Med Chem; 2006 Jan; 49(2):748-59. PubMed ID: 16420060
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Chiral resolution, determination of absolute configuration, and biological evaluation of (1,2-benzothiazin-4-yl)acetic acid enantiomers as aldose reductase inhibitors.
    Hao X; Qin X; Hussain S; Parveen S; Zhang W; Fu F; Ma B; Zhu C
    J Enzyme Inhib Med Chem; 2015; 30(5):846-51. PubMed ID: 25431147
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Structure of human aldose reductase holoenzyme in complex with statil: an approach to structure-based inhibitor design of the enzyme.
    El-Kabbani O; Ramsland P; Darmanin C; Chung RP; Podjarny A
    Proteins; 2003 Feb; 50(2):230-8. PubMed ID: 12486717
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Synthesis of organic nitrates of luteolin as a novel class of potent aldose reductase inhibitors.
    Wang QQ; Cheng N; Zheng XW; Peng SM; Zou XQ
    Bioorg Med Chem; 2013 Jul; 21(14):4301-10. PubMed ID: 23683835
    [TBL] [Abstract][Full Text] [Related]  

  • 36. How reliable are current docking approaches for structure-based drug design? Lessons from aldose reductase.
    Zentgraf M; Steuber H; Koch C; La Motta C; Sartini S; Sotriffer CA; Klebe G
    Angew Chem Int Ed Engl; 2007; 46(19):3575-8. PubMed ID: 17394265
    [No Abstract]   [Full Text] [Related]  

  • 37. Design and synthesis of potent and multifunctional aldose reductase inhibitors based on quinoxalinones.
    Qin X; Hao X; Han H; Zhu S; Yang Y; Wu B; Hussain S; Parveen S; Jing C; Ma B; Zhu C
    J Med Chem; 2015 Feb; 58(3):1254-67. PubMed ID: 25602762
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Stereospecific recognition of a spirosuccinimide type aldose reductase inhibitor (AS-3201) by plasma proteins: a significant role of specific binding by serum albumin in the improved potency and stability.
    Kurono M; Fujii A; Murata M; Fujitani B; Negoro T
    Biochem Pharmacol; 2006 Jan; 71(3):338-53. PubMed ID: 16324683
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Studies on the synthesis and structure-activity relationships of 5-(3'-indolal)-2-thiohydantoin derivatives as aldose reductase enzyme inhibitors.
    Büyükbingöl E; Süzen S; Klopman G
    Farmaco; 1994 Jun; 49(6):443-7. PubMed ID: 8074787
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Substituted pyrrol-1-ylacetic acids that combine aldose reductase enzyme inhibitory activity and ability to prevent the nonenzymatic irreversible modification of proteins from monosaccharides.
    Nicolaou I; Demopoulos VJ
    J Med Chem; 2003 Jan; 46(3):417-26. PubMed ID: 12540241
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.